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Abstract 
Carcinogenesis is the transformation of a normal cell into a cancerous cell.  Cancer 
chemoprevention is the use of natural and synthetic compounds to stop carcinogenesis. These 
compounds have been labeled chemopreventives and they take advantage of the human body’s 
natural defenses to stop carcinogenesis. Chalcones have demonstrated antibacterial, antifungal, 
antitumor, and anti-inflammatory properties. In this project, chalcones and their derivatives are 
synthesized with the goal to be used as possible chemopreventives. We believe that when tested 
on cancer cell lines, the boronic acid derivative will show greater chemopreventive activity 
because of the boronic acid’s increased bioavailability. We have synthesized and characterized a 
series of methoxy and boronic acid chalcones via adol condensation. Our synthetic methodology 
included the conversion of hydroxybenzaldehydes into alkoxybenzaldehydes via Williamson 
Ether Synthesis, followed by a Clasien-Schmidt condensation between the alkoxybenzaldehydes 
and an acetophenone. The synthesized chalcones were characterized 1 H, 13 C, and 2D NMR 
spectroscopy and were shown to exhibit yields ranging from 58% to 91%.    
3 
CHAPTER 1 
Introduction 
 Cancer can best be described as the disease of mayhem. This disease goes against the 
natural order in which normal cells operate. Cancer typically attacks the organs in the human 
body, by causing the uncontrollable growth of transformed cells. During this process, the human 
genome acquires mutant alleles of proto-oncogenes, tumor suppressors and other genes that can 
regulate cell proliferation. This accumulation of a transformed cell form a tumor which can be 
either be benign (localized/noninvasive) or malignant (metastatic/invasive). In the majority of 
cases it is the malignant tumors that are responsible for the largest part of deaths from cancer. 
This disease is a complicated, multi step process that takes years to develop in humans, and can 
involve a number of genes. Combinations of mutated-genes bring about the process of 
carcinogenesis and studies have shown that a single gene mutation is not enough to start the 
process of cancer. Carcinogenesis, the transformation of a normal cell to a cancer cell, can be 
influenced by a person’s genetic makeup or by environmental factors.  
 Cancer has become a growing health epidemic plaguing the United States. It is estimated 
that there is about 1.5 million new cancer cases in the United States and approximately five 
hundred thousand deaths from cancer (Yadav, Prasad, Sung, & Aggarwal, 2011). Although 
cancer is a worldwide problem, the number of cancer incidence rates, the rates with which the 
disease is diagnosed, varies from country to country as well as regions to regions. According to 
the International Agency for Research on Cancer, African Americans, in the United States of 
America have the highest incidence rate of prostate cancer compared to any race in the world. 
Regionally cancer varies dramatically (Weinberg, 2007). For instance, African Americans in 
Louisiana have a higher incidence of lung cancer while Korean Americans in Los Angeles 
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experience a higher incidence of pancreas cancer. In any case, cancer is an occurring issue across 
the world.   
 1.1 Formation of Cancer 
 All cancers have a genetic basis. The accumulation of mutations in DNA is what brings 
about the formation of cancer. The blue print of DNA is genes, whose main responsibility is to 
keep cells in balanced. There are two known categories of genes that are associated with cancer, 
proto-oncogenes and tumor suppressor genes. The elimination or transformation of these two 
genes can result in the formation of cancer. Proto-oncogenes code for proteins that help with cell 
growth and differentiation. As a result of DNA damage, these normal cellular genes become 
inactivated and transform themselves into oncogenes. Oncogenes promote cell growth and are 
expressed in high level in tumor cells. Tumor suppressor genes are genes that protect the cells 
from advancing down the path towards cancer. Inactivation of these genes causes cell 
proliferation (cell growth). The formation of cancer has been found to be the cause of oncogenes 
rather than the tumor suppressor genes. This is because in order for the oncogene to be activated 
it only takes one mutation, whereas tumor suppressor genes require multiple hits to become 
activated (Weinberg, 2007). 
  The risk of developing cancer can be attributed to random mutations, inherited mutations, 
viral infections and or environmental factors (Weinberg, 2007). Inherited mutations are pre-
dispositions that cause an abnormal gene that is passed from generation to generation. A 
common misconception about inherited mutations is that a person will have cancer. In actuality, 
persons with inherited mutations only inherit an abnormal gene that has the potential to bring 
about cancer. There is still a possibility of that person never developing cancer.  
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 The known or suspected causes of human cancers can vary from region to region and is 
based on a person environment or life style choices. Environmental factors are the leading causes 
in the formation of cancer. A person is exposed to many carcinogens on a daily basis. Studies 
have determined that only 5-10 % of cancer is caused by inheritance of mutated genes while 90-
95% of cancer has been linked to lifestyles and environmental factors (Yadav et al., 2011). 
Infectious agents can lead to the transformation of a host cell, but is a preventable cause of 
cancer (Carrillo-Infante, Abbadessa, Bagella, & Giordano, 2007). To combat a person’s constant 
exposure to carcinogens developing a therapeutic that can prevent carcinogenesis would be 
highly beneficial.  
1.2 Cancer Cell Characteristics 
 Every cell goes through the cell cycle. The cell cycle for eukaryotes is divided into two 
major periods: interphase, the process in which the cell grows, and mitosis, the phase where cell 
division occurs. The duration of the cell cycle of a cancerous cell is sometimes faster or 
prolonged than that of a normal cell (Diaz-Moralli, Tarrado-Castellarnau, Miranda, & Cascante, 
2013). Within the cell cycle, check points are used to monitor and regulate the progression of a 
cell. Check points are designed to ensure that damaged or incomplete DNA is not passed to a 
daughter cell. The cell cycle utilizes certain enzymes, such as tumor suppressors, to inhibit the 
cell cycle if a cell becomes cancerous.    
 Cancer cells exhibit behaviors found in a normal cell during development, differentiation 
and homeostasis, but do not show normal regulatory control over these functions. There are 
certain distinct properties of cancer cells that differentiate themselves from normal cells. Most 
normal cells have a limited potential to divide, where as cancer cells show no limitations towards 
divisions. Cancer cells do not undergo contact inhibition. They are invasive by creating new 
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network of blood sources (angiogenesis) and most importantly they do not undergo apoptosis 
naturally. Cancer cells are also known to metabolize glucose through glycolsis without the 
formation of ATP and have a high pH levels within the cell. Given that cancer requires an acidic 
and low oxygen environment to flourish, cancer patients have a very high blood pH of 6.5- 7.0 or 
lower. Another factor that is common in all cancers is inflammation. Inflammation is a biological 
response to harmful stimuli, and is classified into two stages; acute and chronic. Chronic 
inflammation is known to be associated with most chronic illnesses, including diabetes, obesity 
and cancer. Studies have shown that chronic inflammation is mandatory for the induction of an 
immunosuppressive environment, due to the high concentrations of oxygen (Mikirova, Casciari, 
Rogers, & Taylor, 2012). 
1.3 Cancer Treatments  
 Treatments for cancer are prescribed based on a variety of factors that are specific to the 
patients’ individual circumstances ("Overview: Cancer Treatments - Cancer," 2012). These 
factors include the cancer stage, patients’ age, medical history and overall health. Each form of 
cancer is different and requires different treatment approaches. However, the most common 
approaches are radiation and chemotherapy. Both forms of therapy have the potential of 
damaging both cancer cells and healthy cells. There are also newer forms of treatments emerging 
on the frontier of cancer treatments and are in clinical trials. 
 Both surgical oncology and radiation therapy is used to treat localized cancer in the body. 
Both forms are focused on the management of cancer. Surgery physically removes a tumor or is 
sometimes used as a prevention measure. Radiation therapy is a method of treating cancer using 
high-energy waves with the goal to kill cancer cells or limit their ability to grow and divide. 
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 Chemotherapy utilizes combinations of drugs that are either administered orally or 
intravenously. Chemotherapy drugs target cells in the body that divide and grow at a rapid rate 
("Overview: Cancer Treatments - Cancer," 2012). This form of treatment is commonly 
prescribed to patients’ whose cancer is not localized. Chemotherapy can be used to reduce 
symptoms as well as the pain associated with cancer. The duration of treatment is dependent on 
the type of cancer, the area and a person’s individual response from their body to the drugs.  
 Chemotherapy drugs can be divided into several groups based on the following factors of 
how they work, their chemical structures, and their relationship to another drug ("What are the 
different types of chemotherapy drugs?," 2012). Alkylating agents work in all phases of the cell 
cycle. Temodar® is an alkylating agents used to damage DNA and prevent cancer cells from 
reproducing. Antimetabolites interfere with DNA and RNA growth during the S phase. Some 
examples of antimetabolites are 5-fluorouracil, 6-mercaptopurine, Xeloda®, Hydroxyurea, and 
Methotrexate. Mitotic inhibitors are plant alkaloids and other compounds derived from natural 
products. Taxol® is an example of a mitotic inhibitor that stops mitosis or inhibit enzymes from 
making proteins needed for cell reproduction. 
 Doctors also rely on clinical drugs and studies as an option to treat cancer patients. 
Clinical trials are studies that utilize volunteers to take part in test of new drugs or procedures. 
Amongst these new classes of drugs and procedures are electrochemotherapy and 
chemopreventives. Electrochemotherapy combines injection of a chemotherapeutic drug 
followed by the application of high-voltage electric pulses to the tumor site (Heller, Gilbert, & 
Jaroszeski, 1999). Chemopreventive agents interfere with a disease process by halting 
carcinogenesis. 
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CHAPTER 2 
Literature Review 
2.1 Flavonoids 
 Phytohemicals are chemical compounds made by plants to help protect cells against 
oxidative damage. Flavonoids are a group of compounds found in plants and serve as defense 
mechanisms against herbivores and provide the intense pigments in flowers, fruits and leaves 
(Dyrager, 2012).This group of compounds is made up of a structural class known as 
polyphenols. Polyphenols are unique for the reason that they can be found within nature, but can 
be synthesized.  Flavonoids are recognized for their antioxidant properties, and are referred to as 
“natures’ biological response” because of their ability to modify the body’s reaction to allergens 
and viruses.  
 Dietary agents from fruits, vegetables, and spices are beginning to draw attention from 
both the public and medical community because of their ability to suppress a variety of diseases 
(Yadav et al., 2011). There is a variety of flavonoids and each kind is divided into classes based 
off their molecular structures. The most common flavonoids found in the human diet are 
flavones, flavonols, isoflavones, and neoflavones (Figure 1). Flavonoids are made up of three 
heterocyclic rings, A, B & C. The common component within all the flavonoids is the ketone 
functional group located in the C ring. This is believed to give the compound its activity as well 
as its dynamic color, yellow. Given that flavonoids are distributed in the human diet they are 
believed to be non-toxic compounds (Dyrager, 2012).  Because they naturally occur and are 
easily synthesized, they are appealing drug candidates, and can be classified as a 
chemopreventive. 
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Figure 1. Common flavonoids.  
2.2 Chalcones 
 Chalcones (Figure 2) are the major intermediates in the biosynthesis of flavonoids. These 
compounds and their derivatives can either be isolated from natural products or synthesized 
using classic synthetic chemistry. Chalcones are being considered as anticancer agents because 
they demonstrate variety of properties such as, antibacterial, antitumor and anti-inflammatory. 
Chemically, they consist of two aromatic rings joined by a three carbon α, β- unsaturated 
carbonyl system.  
O
A B
6
5
4
3
2
2'
6'
5'
3'
4'
β
α
 
Figure 2. General structure and numbering of a chalcone. 
2.2.1 Synthesis of chalcones. Chalcones can be derived both naturally and synthetically.  
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2.2.1.1 Natural biosynthesis of chalcones. Chalcones participate in the biosynthetic 
pathways of flavonoids. Naturally, they are produced as a plant’s secondary metabolism 
mechanism to aid in the growth and development of a plant. Secondary metabolisms play a key 
role in keeping all of the plants’ system working properly by severing as defense mechanisms. In 
a stepwise addition of L-phenylalanine, an amino acid, as the starting compound for the 
flavonoid skeleton is formed (Scheme 1). In this reaction ammonia is removed to form a trans-
cinnamate that is converted to a p-coumarate. The p-coumarate  then undergoes ligation with 
CoA-SH to form 4-coumaroyl-CoA (Yadav et al., 2011). From there 4-coumaroyl-CoA can go 
through a naringenin-chalcone synthase and form a naringenin-chalcone. This chalcone can be 
extracted from an apple tree leaf. 
H2
C C COO-
NH3+
H
COO-Phenylalanine 
Ammonia-lyase
HO
COO-trans-cinnamate 4-
mono oxygenase
CoA-S
O
HO
4-coumarate 
CoA ligase
Naringenin-chalcone 
synthase
HO
O O
O
CoA-S O
CoA-SH
O
OH
OH
HO OH
L-phenylalanin trans-cinnamate
p-coumarate
4-coumaroyl-CoA
Naringenin chalcone
 
Scheme 1. Natural synthesis of chalcones. 
2.2.1.2 Synthetic biosynthesis of chalcones. Synthetic chalcones are less complicated to 
form than a naturally occurring chalcone. The key to forming a chalcone is the formation of the 
enone functional group. An aldol condensation is an organic reaction involving an enol reacting 
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with a carbonyl compound to form a β-hydroxyketone, followed by a dehydration to give a 
conjugated enone. The more common way to form a chalcone is the Clasien-Schmidt 
condensation. This reaction is an aldol condensation between a benzaldehyde and an 
acetophenone in the presents of a base in a polar solvent (Scheme 2).  
CH3
O
+ H
O O
base
 
Scheme 2. Claisen-Schmidt condensation of a chalcone.  
Recently different reactions have been used to form chalcones (Scheme 3). Scheme 3, 
reaction I is the Suzuki coupling between cinnamoyl chloride and phenylboronic acid has been 
reported but formed chalcones in yields ranging from 68%- 93% (Eddarir, Cotelle, Bakkour, & 
Rolando, 2003). Another approach was the Heck coupling (Scheme 3, reaction II) with an aryl 
halide with styrenes in the presence of carbon monoxide with yields ranging from 24%-65% 
(Reichwald, Shimony, Sacerdoti-Sierra, Jaffe, & Kunick, 2008). Between both these reactions 
the more promising yields came from the Suzuki coupling.  
B
OH
OH +
Cl
O
O
I
+
I.
II. + CO DMF
Toluene
Pd/base
Pd/ligand
 
Scheme 3. Suzuki cross-coupling and Heck reaction formation of a chalcone. 
2.2.2 Application of chalcones. 
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2.2.2.1 Antibacterial. Chalcones have a broad spectrum of antibacterial activities, and 
their diverse applications have become popular in the medical field. The equilibrium between the 
open chalcone structures allows a variety of substitution on their rings which results in different 
effects (Ávila, Smânia, Monache, & Smânia Júnior, 2008).  Licochalcone is a chalcone obtained 
from the glycyrrhiza glabra, a root in which licorice flavor comes from, has shown the ability 
disrupt the cell membrane (Sivakumar et al., 2012).  This is useful in the medical field where 
they use chalcones to coat medical devices to prevent the colonization of bacteria. 
2.2.2.2 Anti-inflammatory. Inflammation associated with cancer has been linked to the 
excess production of nitric oxide, a free radical produced by the body. This nitric oxide has the 
potential to destroy normal tissue during acute and chronic inflammation (Honda et al., 2000). 
This is can also be correlated to the process of carcinogenesis (Honda et al., 2000). 
Broussochalcone is a natural chalcone isolated from the Moraceae, a plant from the fig family. 
This chalcone exerted potent antioxidant activity and inhibited the inducible nitric oxide synthase 
(iNOS) expression in macrophages (Won et al., 2005). This inhibition of nitric oxide production 
demonstrates how chalcones are potential anti-inflammatory and cancer chemopreventive drugs.  
2.2.2.3 Antitumor. Invasion is the trademark of malignant tumors and usually leads to the 
major cause of death in cancer patients (Mukherjee et al., 2001). If a cell is allowed to replicate 
itself, its end result is the formation of a tumor. Chalcones contain an enone in its structure which 
have been shown to reduce tubulin assembly (Johnson et al., 2007). Tubulins are composed of 
microtubules which is a key component of the cytoskeleton of protein. Chalcones bind to the 
tublin and prevent it from polymerizing into microtubules (Bandgar, Gawande, Bodade, Totre, & 
Khobragade, 2010). When the cytoskeleton of a cell is destroyed it results in cell death. The 
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obstruction of the microtubule system for the eukaryotic cells can be considered an important 
target for the development of antitumor agents (Kong et al., 2010). 
2.2.3 Chalcones as a chemopreventive. Carcinogenesis is a complex and a multistage 
process in which a normal cell is transformed into a cancer cell. The human body is naturally 
equipped with mechanisms to stop a transformed cell from continuing in the cell cycle by 
utilizing the check points within the cycle and tumor suppressor genes. Chemopreventives are 
synthetic drugs, whose structures are similar to compounds found in nature, and improve or 
facilitate those processes the body uses to interrupt carcinogenesis. The goal as a 
chemopreventive is to protect cells from carcinogens.  
There are nine classes of chemopreventive drugs, (i) oxidizable diphenols and quinines, 
(ii) Michael reations acceptors (olefins or acetylenes conjugated to electron withdrawing groups), 
(iii) isothiocyanates, (iv) hydroperoxides, (v) trivalent arsenic derivatives, (vi) divalent heavy 
metal cations (Hg2+ and Cd2+), (vii) vicinal dithiols, (vii) 1,2-dithiole-3-thiones, and (ix) 
carotenoids and other conjugated polymers. These compounds induce phase II enzymes that 
detoxify electrophiles and serve as an indirect antioxidant. Phase 2 drug-metabolizing enzymes, 
glutathione S-transferases (GST) have the ability to conjugate Glutathione (GSH) and thereby 
detoxify cellular environments (A. T. Dinkova-Kostova, Massiah, Bozak, Hicks, & Talalay, 
2001). Glutathion is tripeptides produced naturally in humans, and with respect to cancer GSH 
metabolism is ablet to play both protective and pathogenic roles (Balendiran, Dabur, & Fraser, 
2004). Michael acceptors, cinnamates, chalcones, coumarins and curcuminods, have some type 
of relationship between their conjugated benzylidene ketone structure that raises GSH levels in 
cells (A. T. Dinkova-Kostova et al., 2001).    
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Chalcones have been linked to inducing phase II enzymes (Albena T. Dinkova-Kostova, 
Abeygunawardana, & Talalay, 1998). These enzymes provide protection against toxic chemical 
species. Studies have shown that an elevation of phase II enzymes show a relationship with 
protecting a cell against chemical-induced carcinogenesis (Bandgar et al., 2010). An approach 
for protecting a cell is decreasing the metabolic enzymes response for generating reactive 
species, while increasing phase II enzymes that can deactivate radicals (Bandgar et al., 2010).  
For these reasons, cancer chemopreventives have become an attractive topic for the 
pharmaceutical industry.  
Other studies have also shown that chalcones have been effective in activating p53, a 
tumor suppressor gene, resulting in apoptosis (Achanta, Modzelewska, Feng, Khan, & Huang, 
2006).  Many tumors are formed when tumor suppressor p53 becomes inactive, either by 
mutation or by binding to oncoproteins. Oncoprotein MDM2 inhibits tumor suppressor protein 
p53, by binding to its transactivation domain. When MDM2 is over expressed it disables a 
genome checkpoint and allows the cell cycle to generate defective cells. Chalcones inhibit 
MDM2 in which releases p53 (Stoll et al., 2001).  
2.3 Boron 
2.3.1 Origins. Boron is a non-metallic element, which can be found abundantly in nature 
only when paired with sodium or carbon. Boron is required for normal growth and health of the 
body, making it essential for life.  American adults consume more boron than any other essential 
trace elements such as copper or magnesium (Hunt, 2012). Small amount of boron compounds 
play a strengthening role in cell walls of plants. This element is present in nuts, fresh fruits, green 
vegetables as well as a main ingredient in multivitamins. Boron is also used in cosmetic products 
as a preservative and pH adjuster ("Part 3 Trace Elements 3 164 General information Chemistry 
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Boron is a," 2010). Boron containing compounds have found a common use in synthetic organic 
chemistry in addition to applications in the biomedical field as a treatment for HIV, obesity, 
diabetes and cancer (Cambre & Sumerlin, 2011). 
 2.3.2 Biological functions. Traces of boron can be located throughout the human body, 
the main source being the consumption of plants in our diet. Boron is present in human plasma 
(0.017-0.191 µg/mL) and in the liver (1.1-5.4 µg/g) (Hunt, 2012). In the human body, boron is 
used to support biological functions such as inducing calcium and insulin metabolism as well as 
bone growth. It is believed that boron improves the human body natural ability to absorb calcium 
and magnesium. Diets depleted in boron have been shown to affect both the immune and nervous 
systems (Cui et al., 2004). Many disease conditions, such as arthritis, osteoporosis, and 
menopausal symptoms, are managed by boron.  Boron is also known to alter human steroid 
hormone levels, mainly testosterone and estrogen (Cui et al., 2004). Evidence from animal 
experiments suggests that boron is essential during the rapid cell replication during the 
fertilization cycles. 
2.4 Boronic Acid 
Boronic Acid is a Lewis acid belonging to the larger class of organoboranes (Figure 3). 
This compound is stable and is easily handle which makes them an attractive class of synthetic 
intermediates (Boronic Acids, 2005). Chemically, they consist of trivalent boron atom bonded to 
one alkyl/aryl substituent and two hydroxyl groups, R-B(OH)2. Their empty p-orbital on Boron 
allows the interconversion from sp2 to sp3 hybridization in the presences of a Lewis Base. These 
compounds are unique and versatile which allows them to be used for the formation of C-C 
bonds, asymmetric synthesis, molecular sensing, therapeutic agents and enzyme inhibitors 
(Cambre & Sumerlin, 2011). Boronic acid is low in toxicity and degradation into 
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environmentally friendly boric acid allows it to be considered a “green” compound. There are a 
variety of Boronic acids but arylboronic acids remain the most acknowledged class of boronic 
acids. 
B R
II
RIR
 
Borane 
B OHRIR
 
Borinic Acid 
B OHOHR
 
Boronic Acid 
B OR
I
ORIR
 
Boronic Ester 
(RI = alkyl or aryl) 
Figure 3. Oxygenated organoboron compounds.  
2.4.1 Synthesis of boronic acid. Boronic acids are widely used in organic chemistry as 
building blocks or intermediates. These compounds are not naturally occurring but are 
commercially available. They can also be synthesized through several different methods. The 
most familiar way is through organometallic compounds based on lithium or magnesium 
grignard with a borate ester (Scheme 4, Reaction I).  Another method is a transmetallation 
reaction involving a trialkylsiyl derivative with a boron halide (Scheme 4, Reaction II). Boronic 
acids are also popular cross-coupling intermediates in natural products synthesized in medicinal 
chemistry. An example is the Suzuki-Miyaura cross-coupling reaction for synthesis of dienes and 
other unsaturated units present in many natural products (Scheme 4, Reaction III). Presently, this 
method is used in the pharmaceutical industry for the synthesis of PS-341, a new cancer therapy 
in Phase I clinical evaluation for advanced cancer patients as an enzyme inhibitor (Yang, Gao, & 
Wang, 2003).  
2.4.2 Boronic acid as a chemopreventive. Boronic acid derivatives are of interest in 
drug development because of their diverse characteristics towards cancers. These compounds are 
known to have a role in the controlling of normal inflammatory response, as it relates to the 
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production of various cell signaling (Hunt, 2012). The “potential mode of action” is through the 
synthesis or activation of metabolites that regulate growth (Cui et al., 2004).   
SiMe3 BBr3 BBr2 B(OH)2H3O+
R R R
X
R
X= Br, I
i. RM
ii. B(ORI)3 B(OR
I)2
R
H3O+
X
R
(RIO)2B-B(ORI)2 
or HB(ORI)2
Pd0, base
B(ORI)2
R H3O
+
X= Br, I, OTf
I.
II.
III.
 
Scheme 4. Common  methods for the synthesis of arylboronic acids. 
Boronic acid was also identified as a potential inhibitor of human cancer in cell 
proliferation and angiogenesis (Kong et al., 2010).  Other characteristic boronic acids have is 
their ability to affect the cell pH level (Cambre & Sumerlin, 2011). When added on a phenyl 
ring, it allows the pKa to be tuned so that boronic acid containing polymers can be employed in a 
physiologically relevant pH range (Cambre & Sumerlin, 2011).  It is the presence of the 
hydroxyl groups that gives a compound its hydrophilicity (A. T. Dinkova-Kostova et al., 2001). 
Cancer cells have a pH between 6.0-7.0, being very acidic, while Boronic acid derivatives have a 
moderate pH of 9.0-10.0 and while maintaining air stability (Kong et al., 2010). Antibiotics 
containing Boron inhibit DNA, RNA & protein synthesis and or disrupt membrane permeability. 
There are several potential Boronic acid binding sites involved in prostate cancer (Cui et al., 
2004). The drug Bortezomib® is a compound containing a Boronic acid group which is used in 
chemotherapy. This drug was the first proteasome inhibitor, a drug that blocks the breakdown of 
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proteins, approved by the U.S. Food & Drug Administration in May of 2003 to treat myeloma, 
with no toxicity issues.  
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CHAPTER 3 
Experimental 
3.1 General Procedure 
 All chemicals were reagent grade from Acros Organics Incorporated and used as 
purchased. The moisture sensitive reactions were performed under an inert atmosphere of dry 
nitrogen with dried solvents. 4-hydroxybenzaldehyde was converted into 4-alkoxybenzaldehyde 
via Williamson Ether synthesis.  The Claisen-Schmidt condensation was then utilized to convert 
4-alkozybenzaldehyde into both the methoxychalcones as well as the boronic acid chalcones.  
Each compound prepared was then characterized by 1H and 13C NMR spectra were recorded on a 
VANCE II at 400 and 100 MHz. The coupling constant (J) are reported in Hz. Melting point 
ranges were ran on MEL TEMP and recorded in degree Celsius .  
3.2 Synthesis of 4-alkoxybenzaldehydes (1a-8a) 
 4-Hydroxybexnzaldehyde (50 mmol, 6.106 g) and potassium carbonate, K2CO3 (50 
mmol, 6.91 g) were added to 2-butanone (75 mL) in a 250 mL round bottom flask. The reaction 
mixture was heated to 60-65 °C for 30 minutes, followed by the addition of 1-bromoalkane 
(C3H7Br to C12H25Br, 50 mmol) was added drop wise and the reaction mixture was heated to 
reflux for 18 hours. The solvent was evaporated under reduced pressure on a rotary evaporator, 
then separated with diethyl ether (125 mL). Unreacted starting materials were washed with 
distilled water and 10% sodium hydroxide, NaOH. Ether layer was dried over magnesium 
sulfate, MgSO4, then evaporated and distilled to give 4-alkoxybenzaldehydes 1a-8a. All resulting 
compounds were either pale yellow or yellow liquids, but some resulted in solids. 
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Scheme 5. Williamson Ether synthesis of 4-alkoxybenzaldehyde. 
 3.2.1 4-(pentyloxy)benzaldehyde (1a). 4-hydroxybenzaldehyde (6.121 g, 50 mmol) and 
1-bromopentane (7.592 g, 50 mmol) were reacted according to the general procedure. A pale 
yellow liquid was obtained with a yield of 69% (6.627 g). 1H NMR (301 MHz, Chloroform-d) δ 
9.86 (d, J = 3.1 Hz, 1H), 8.13 – 7.50 (m, 2H), 7.14 – 6.61 (m, 2H), 4.02 (t, J = 6.4 Hz, 2H), 1.81 
(q, J = 7.5, 6.5 Hz, 2H), 1.69 – 1.16 (m, 4H), 1.13 – 0.64 (m, 3H). 
 3.2.2 4-(hexyloxy)benzaldehyde (2a). 4-hydroxybenzaldehyde (6.127 g, 50 mmol) and 
1-bromohexane (8.294 g, 50 mmol) were reacted according to the general procedure. A yellow 
liquid was collected with a  yield of 68% (6.976 g). 1H NMR (301 MHz, Chloroform-d) δ 9.87 
(d, J = 3.6 Hz, 1H), 8.17 – 7.57 (m, 2H), 7.19 – 6.61 (m, 2H), 4.03 (q, J = 6.5, 5.4 Hz, 2H), 1.79 
(dd, J = 13.5, 7.0 Hz, 2H), 1.39 (d, J = 45.2 Hz, 9H), 1.16 – 0.71 (m, 4H). 
 3.2.3 4-(heptyloxy)benzaldehyde (3a). 4-hydroxybenzaldehyde (6.111 g, 50 mmol) and 
1-bromoheptane (8.968 g, 50 mmol) were reacted according to the general procedure. A yellow 
liquid/solid matter was obtained with a  yield of  61% (6.791 g). 1H NMR (301 MHz, 
Chloroform-d) δ 10.16 – 9.67 (m, 1H), 8.15 – 7.72 (m, 2H), 7.44 – 6.85 (m, 2H), 4.02 (dd, J = 
7.5, 5.8 Hz, 2H), 1.80 (dq, J = 14.1, 6.9, 6.4 Hz, 2H), 1.56 – 1.06 (m, 11H), 1.06 – 0.75 (m, 3H). 
 3.2.4 4-(octyloxy)benzaldehyde (4a). 4-hydroxybenzaldehyde (6.104 g, 50 mmol) and 1-
bromooctane (9.716g, 50 mmol) were reacted according to the general procedure. An orange 
liquid was observed with a yield of 30% (3.492 g). 1H NMR (301 MHz, Chloroform-d) δ 9.87 (s, 
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1H), 7.82 (d, J = 7.9 Hz, 2H), 7.28 – 6.52 (m, 2H), 4.03 (t, J = 6.2 Hz, 2H), 3.39 (t, J = 6.6 Hz, 
0H), 1.81 (h, J = 6.6 Hz, 2H), 1.69 – 1.08 (m, 15H), 1.08 – 0.57 (m, 5H). 
 3.2.5 4-(nonyloxy)benzaldehyde (5a). 4-hydroxybenzaldehyde (6.913 g, 50 mmol) and 
1-bromononane (10.377 g, 50 mmol) were reacted according to the general procedure. A yellow 
solid was gathered with a yield of 28% (3.528 g). 1H NMR (301 MHz, Chloroform-d) δ 9.86 (s, 
1H), 7.81 (d, J = 8.5 Hz, 1H), 6.97 (d, J = 8.5 Hz, 2H), 4.02 (t, J = 6.6 Hz, 2H), 1.78 (q, J = 6.9 
Hz, 2H), 1.58 – 1.13 (m, 8H), 0.87 (t, J = 6.5 Hz, 2H). 
 3.2.6 4-(decyloxy)benzaldehyde (6a). 4-hydroxybenzaldehyde (6.177 g, 50 mmol) and 
1-bromodecane (11.079 g, 50 mmol) were reacted according to the general procedure. A yellow 
solid/liquid matter was observed with a yield of 51% (6.707 g). 1H NMR (301 MHz, 
Chloroform-d) δ 9.86 (d, J = 1.8 Hz, 1H), 8.06 – 7.66 (m, 1H), 7.17 – 6.58 (m, 2H), 4.28 – 3.57 
(m, 2H), 1.80 (t, J = 7.1 Hz, 1H), 1.56 – 1.08 (m, 8H), 1.02 – 0.64 (m, 2H). 
 3.2.7 4-(undecyloxy)benzaldehyde (7a). 4- hydroxybenzaldehyde (6.176 g, 50 mmol) 
and 1-bromoundecane (11.776 g, 50 mmol) were reacted according to the general procedure. A 
yellow solid with a yield of 52% (7.250 g) was collected. 1H NMR (301 MHz, Chloroform-d) δ 
9.87 (d, J = 3.1 Hz, 1H), 8.06 – 7.59 (m, 2H), 6.98 (d, J = 8.2 Hz, 2H), 4.46 – 3.72 (m, 2H), 2.16 
– 1.73 (m, 1H), 1.73 – 1.04 (m, 11H), 1.08 – 0.41 (m, 3H). 
 3.2.8 4-(dodecyloxy)benzaldehyde (8a). 4-hydroxybenzaldehyde (6.109 g, 50 mmol) 
and 1-bromododecane (12.482 g, 50 mmol) were reacted according to the general procedure. A 
pale yellow solid was collected with a yield of 67% (9.781 g). 1H NMR (301 MHz, Chloroform-
d) δ 9.87 (d, J = 3.1 Hz, 1H), 8.06 – 7.59 (m, 2H), 6.98 (d, J = 8.2 Hz, 2H), 4.46 – 3.72 (m, 2H), 
1.80 (p, J = 6.7 Hz, 1H), 1.73 – 1.04 (m, 11H), 1.08 – 0.41 (m, 3H). 
3.3 Synthesis of 4-alkoxymethoxychalcones (1b-8b) 
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 In a 100 mL round bottom 4-methoxyacetophenone (equal molar equivalence) was 
dissolved in ethanol (20 mL). 10% NaOH (5 equivalence) was added and the reaction mixture 
was stirred for 30 minutes at room temperature. Then 4-alkoxybenzaldehyde 1a-8a (1.000 g) was 
added to the reaction mixture that was further stirred for 18 hours until pale yellow precipitates 
appeared. Crushed ice (35 mL) was added to the solid mass and the reaction was neutralized with 
dilute HCl. The products 1b-8b was obtained as yellow solids, which were filtered and 
recrystallized from ethanol. 
O
CH3
O
+ H
O
OR O OR
NaOH
EtOH
H3C H3C
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Scheme 6. Claisen-Schmidt condensation of 4-alkoxymethoxychalcone. 
 3.3.1 (E)-1-(4-methoxyphenyl)-3-(4-(pentyloxy)phenyl)prop-2-en-1-one (1b).  4-
methoxyacetophenone (1.009 g, 5.2 mmol) and 4-(pentyloxy)benzaldehyde (0.788 g, 5.2 mmol) 
were reacted according to the general procedure. Yellow solids were obtained with a yield of 
68% (1.146 g). m.p. 94-99 °C; 1H NMR (301 MHz, Chloroform-d) δ 8.04 (d, J = 8.2 Hz, 1H), 
7.79 (d, J = 15.5 Hz, 0H), 7.60 (d, J = 8.4 Hz, 1H), 7.44 (d, J = 18.6 Hz, 1H), 6.96 (dd, J = 17.4, 
8.2 Hz, 2H), 4.44 – 3.46 (m, 3H), 2.51 (d, J = 5.6 Hz, 0H), 1.81 (s, 2H), 1.46 (d, J = 14.8 Hz, 
3H), 0.96 (q, J = 7.0, 6.1 Hz, 3H). 
 3.3.2 (E)-1-(4-(hexyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (2b). 4-
methoxyacetophenone (1.002 g, 4.85 mmol) and 4-(hexyloxy)benzaldehyde (0.731 g, 4.85 
mmol) were reacted according to the general procedure. Pale yellow solids were collected with a 
yield of 81% (1.334 g). m.p. 93-99 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.08 – 7.99 (m, 
2H), 7.77 (d, J = 15.5 Hz, 1H), 7.64 – 7.55 (m, 2H), 7.50 – 7.46 (m, 1H), 7.42 (d, J = 15.6 Hz, 
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1H), 7.00 – 6.96 (m, 2H), 6.94 – 6.89 (m, 2H), 3.99 (q, J = 6.5 Hz, 3H), 3.93 – 3.82 (m, 3H), 
1.88 – 1.69 (m, 3H), 1.46 (tdd, J = 9.5, 5.0, 2.9 Hz, 3H), 1.41 – 1.27 (m, 5H), 0.97 (d, J = 6.6 Hz, 
2H), 0.91 (ddt, J = 7.3, 5.1, 2.1 Hz, 4H). 13C NMR (101 MHz, CDCl3) δ 200.33, 188.75, 163.21, 
161.13, 143.90, 142.26, 131.39, 130.66, 130.07, 129.92, 127.55, 126.97, 124.30, 119.35, 114.87, 
113.74, 68.16, 55.46, 49.84, 31.54, 29.12, 25.67, 25.66, 25.35, 22.72, 22.58, 14.01. 
 3.3.3 (E)- 3-(4-(heptyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (3b). 4-
methoxyacetophenone (0.686 g, 4.54 mmol) and 4-(heptyloxy)benzaldehyde (1.011 g, 4.54 
mmol) were reacted according to the general procedure. Pale yellow solids were gathered with a 
yield of 70% (1.116 g). m.p. 85-94 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.06 – 7.99 (m, 
2H), 7.81 – 7.73 (m, 1H), 7.60 – 7.53 (m, 2H), 7.42 (d, J = 15.6 Hz, 1H), 7.00 – 6.94 (m, 2H), 
6.94 – 6.88 (m, 2H), 4.07 – 3.93 (m, 3H), 3.87 (s, 3H), 1.91 – 1.70 (m, 4H), 1.44 (dddd, J = 9.2, 
5.9, 4.5, 2.9 Hz, 3H), 1.39 – 1.22 (m, 9H), 0.92 – 0.81 (m, 4H).13C NMR (101 MHz, CDCl3) δ 
188.52, 163.02, 160.94, 143.71, 131.18, 129.88, 129.73, 127.33, 119.13, 114.66, 113.55, 67.96, 
55.25, 49.64, 31.56, 28.97, 28.84, 25.77, 25.15, 22.53, 22.40, 13.89.  
 3.3.4 (E)-1-(4-methoxyphenyl)-3-(4-(octyloxy)phenyl)prop-2-en-1-one (4b). 4-
methoxyacetophenone (0.672 g, 4.27 mmol) and 4-(octyloxy)benzaldehyde (1.006 g, 4.27 mmol) 
were reacted according to the general procedure. Beige solids; yield 58% (0.914 g); m.p. 94-96 
°C; 1H NMR (400 MHz, Chloroform-d) δ 8.08 – 7.99 (m, 1H), 7.77 (d, J = 15.5 Hz, 1H), 7.63 – 
7.55 (m, 1H), 7.47 – 7.37 (m, 1H), 7.02 – 6.94 (m, 1H), 6.94 – 6.88 (m, 1H), 3.99 (t, J = 6.5 Hz, 
1H), 3.88 (s, 2H), 1.89 – 1.69 (m, 1H), 1.53 – 1.40 (m, 1H), 1.40 – 1.19 (m, 5H), 0.94 – 0.80 (m, 
2H). 13C NMR (101 MHz, cdcl3) δ 188.59, 163.05, 160.96, 143.74, 142.11, 131.22, 130.50, 
129.91, 129.76, 127.38, 126.80, 124.13, 119.18, 114.69, 113.58, 68.01, 55.29, 49.67, 31.63, 
29.16, 28.99, 25.83, 22.56, 13.93. 
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 3.3.5 (E)-1-(4-methoxyphenyl)-3-(4-(nonyloxy)phenyl)prop-2-en-1-one (5b). 4-
methoxyacetophone (0.607 g, 4.03 mmol) and 4-(nonyloxy)benzaldehyde (1.000 g, 4.03 mmol) 
were reacted according to the general procedure. Beige solid were collected with a yield of 68% 
(1.048 g). m.p. 105-106°C; 1H NMR (400 MHz, Methanol-d4) δ 8.01 (d, J = 7.7 Hz, 1H), 7.79 – 
7.71 (m, 1H), 7.70 – 7.65 (m, 1H), 7.60 (d, J = 9.6 Hz, 1H), 7.58 – 7.52 (m, 2H), 7.01 – 6.87 (m, 
2H), 6.68 (d, J = 16.1 Hz, 1H), 3.99 (dt, J = 8.2, 6.4 Hz, 2H), 1.82 – 1.68 (m, 2H), 1.50 – 1.37 
(m, 3H), 1.39 – 1.22 (m, 11H), 0.91 – 0.84 (m, 3H).13C NMR (101 MHz, CDCl3) δ 188.59, 
163.04, 160.96, 143.75, 131.20, 130.50, 129.92, 127.35, 119.14, 114.68, 113.58, 68.00, 55.30, 
31.70, 29.35, 29.21, 29.09, 28.99, 25.83, 22.50, 13.95. 
 3.3.6 (E)- 3-(4-(decyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (6b). 4-
methoxyacetophenone (0.575 g, 3.81 mmol) and 4-(decyloxy)benzaldehyde (1.060 g, 3.81 
mmol) were reacted according to the general procedure. Beige solid were collected with a yield 
of 91% (1.361 g). m.p. 82-97 °C; 1H NMR (400 MHz, Chloroform-d) δ 7.77 (d, J = 15.6 Hz, 
1H), 7.62 – 7.55 (m, 2H), 7.50 – 7.46 (m, 1H), 7.42 (d, J = 15.6 Hz, 1H), 7.02 – 6.94 (m, 2H), 
6.94 – 6.89 (m, 2H), 3.98 (q, J = 6.5 Hz, 3H), 3.88 (s, 3H), 2.50 (d, J = 7.0 Hz, 1H), 1.88 – 1.71 
(m, 3H), 1.52 – 1.18 (m, 18H), 0.93 – 0.80 (m, 4H). 13C NMR (101 MHz, CDCl3) δ 188.60, 
163.04, 160.96, 143.76, 142.13, 131.20, 130.50, 129.92, 129.76, 127.36, 126.78, 124.11, 119.15, 
114.69, 113.58, 68.00, 55.30, 49.67, 31.72, 29.20, 29.14, 28.99, 25.82, 25.19, 22.51, 13.95. 
 3.3.7 (E)-1-(4-methoxyphenyl)-3-(4-(undecyloxy)phenyl)prop-2-en-1-one (7b). 4-
methoxyacetophenone (0.549 g, 3.62 mmol) and 4-(undecyloxy)benzaldehyde (1.006 g, 3.62 
mmol) were reacted according to the general procedure. White solid with a yield 76% (1.121 g) 
were collected. m.p. 95-102 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.06 – 7.99 (m, 1H), 7.77 
(d, J = 15.6 Hz, 0H), 7.63 – 7.54 (m, 1H), 7.42 (d, J = 15.6 Hz, 0H), 7.02 – 6.95 (m, 1H), 6.94 – 
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6.89 (m, 1H), 3.98 (q, J = 6.6 Hz, 1H), 3.88 (s, 1H), 2.50 (d, J = 7.0 Hz, 1H), 1.87 – 1.68 (m, 
1H), 1.53 – 1.09 (m, 10H), 0.92 – 0.78 (m, 2H). 13C NMR (101 MHz, CDCl3) δ 188.76, 163.21, 
161.13, 143.91, 142.28, 131.38, 130.67, 130.08, 129.92, 127.54, 126.96, 124.29, 119.34, 114.87, 
113.75, 68.17, 55.46, 49.84, 31.90, 29.60, 29.32, 29.15, 25.99, 25.36, 22.68, 14.11. 
 3.3.8 (E)-3-(4-(dodecyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (8b). 4-
methoxyacetophenone (0.523 g, 3.44 mmol) and 4-(dodecyloxy)benzaldehyde (1.007 g, 3.44 
mmol) were reacted according to the general procedure. White solids were collected with a yield 
of 70% (1.017 g). m.p. 94-102 °C; 1H NMR (400 MHz, Chloroform-d) δ 8.06 – 8.00 (m, 1H), 
7.77 (d, J = 15.6 Hz, 1H), 7.61 – 7.55 (m, 1H), 7.42 (d, J = 15.6 Hz, 1H), 7.00 – 6.94 (m, 1H), 
6.94 – 6.88 (m, 1H), 4.07 – 3.92 (m, 2H), 3.88 (s, 2H), 1.85 – 1.66 (m, 2H), 1.52 – 1.40 (m, 2H), 
1.40 – 1.21 (m, 14H), 0.92 – 0.79 (m, 3H). 13C NMR (101 MHz, CDCl3) δ 190.58, 188.54, 
163.03, 160.95, 143.72, 142.08, 131.21, 130.48, 129.89, 129.74, 127.36, 124.11, 119.15, 114.68, 
113.57, 67.99, 55.27, 49.66, 31.73, 29.47, 29.41, 29.19, 28.98, 28.86, 25.82, 25.17, 22.55, 13.94. 
3.4 Synthesis of 4-alkoxyboronic acid chalcones (1c-8c) 
 In a 100 mL round bottom 4-acetylphenylboronic acid (equal molar equivalence) was 
dissolved in ethanol (20 mL). 10% NaOH (5 equivalence) was added and the reaction mixture 
was stirred for 30 minutes at room temperature. Then 4-alkoxybenzaldehyde 1a-8a (1.000 g) was 
added to the reaction mixture that was further stirred for 18 hours until pale yellow precipitates 
appeared. Crushed ice (35 mL) was added to the solid mass and the reaction was neutralized with 
dilute HCl. The products 1c-8c was obtained as yellow solids, which were filtered and 
recrystallized from ethanol. 
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Scheme 7. Claisen-Schmidt condensation of 4-alkoxyboronic acid chalcones. 
 3.4.1 4-((E)-3-(4-(pentyloxy)phenyl)acryloyl)phenylboronic acid (1c). 4-
acetylphenylboronic acid (0.853 g, 5.20 mmol) and 4-(pentyloxy)benzaldehyde (1.016 g, 5.20 
mmol) were reacted according to the general procedure.  
 3.4.2 4-((E)-3-(4-(hexyloxy)phenyl)acryloyl)phenylboronic acid (2c). 4-
acetylphenylboronic acid (0.797 g, 4.85 mmol) and 4-(hexyloxy)benzaldehyde (1.005 g, 4.85 
mmol) were reacted according to the general procedure. Yellow solids with a yield 64% (1.46 g) 
were collected. m.p. 184-195 °C;  1H NMR (400 MHz, Methanol-d4) δ 8.04 – 7.96 (m, 1H), 7.90 
(d, J = 7.7 Hz, 0H), 7.75 (d, J = 15.6 Hz, 1H), 7.69 – 7.64 (m, 1H), 7.60 (d, J = 5.6 Hz, 0H), 7.57 
– 7.52 (m, 1H), 6.99 – 6.89 (m, 1H), 6.69 (d, J = 16.1 Hz, 0H), 3.99 (q, J = 6.6 Hz, 1H), 1.76 
(dtt, J = 7.9, 6.4, 5.2 Hz, 2H), 1.54 – 1.42 (m, 2H), 1.42 – 1.27 (m, 3H). 
 3.4.3 4- ((E)-3-(4-heptyloxy)phenyl)acryloyl)phenyloboronic acid (3c). 4-
acetylphenylboronic acid (0.755g, 4.54 mmol) and 4-(heptyloxy)benzaldehyde (1.007 g, 4.54 
mmol) were reacted according to the general procedure. Yellow solids with a yield of 88% 
(1.460 g) was collected. m.p. 121-186 °C; 1H NMR (400 MHz, Methanol-d4) δ 7.93 (d, J = 7.6 
Hz, 1H), 7.84 (d, J = 8.8 Hz, 0H), 7.73 (d, J = 15.5 Hz, 1H), 7.70 – 7.65 (m, 1H), 7.65 (s, 0H), 
7.60 (d, J = 3.5 Hz, 0H), 7.59 – 7.54 (m, 1H), 4.06 (t, J = 6.4 Hz, 0H), 4.00 (dt, J = 7.7, 6.4 Hz, 
2H), 3.89 (s, 0H), 2.25 – 2.03 (m, 1H), 1.77 (dddd, J = 12.7, 8.4, 6.5, 3.3 Hz, 3H), 1.56 – 1.41 
(m, 2H), 1.41 – 1.21 (m, 6H), 1.03 – 0.75 (m, 6H).13C NMR (101 MHz, CD3OD) δ 201.77, 
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191.41, 161.42, 143.31, 133.20, 131.70, 130.10, 129.92, 127.43, 126.84, 126.52, 123.55, 119.38, 
114.55, 31.57, 28.91, 28.79, 25.69, 22.27, 21.56, 13.02. 
 3.4.4 4-((E)-3-(4-(octyloxy)phenyl)acryloyl)phenylboronic acid (4c). 4-
acetylphenylboronic acid (0.710 g, 4.27 mmol) and 4-(octyloxy)benzaldehyde (0.998 g, 4.27 
mmol) were reacted according to the general procedure. Beige solid; yield 58% (0.938 g) 
 3.4.5 4-(E))-3-(4-(nonyloxy)phenyl)acryloyl)phenylboronic acid (5c). 4-
acetylphenylboronic acid (0.667 g, 4.03 mmol) and 4-(nonyloxy)benzaldehyde (1.001 g, 4.03 
mmol) were reacted according to the general procedure. Pale yellow solids were collected with a 
yield of 67% (1.069 g). m.p. 103-164 °C; 1H NMR (400 MHz, Methanol-d4) δ 8.01 (d, J = 7.7 
Hz, 1H), 7.79 – 7.71 (m, 1H), 7.70 – 7.65 (m, 1H), 7.60 (d, J = 9.6 Hz, 1H), 7.58 – 7.52 (m, 2H), 
7.01 – 6.87 (m, 2H), 6.68 (d, J = 16.1 Hz, 1H), 3.99 (dt, J = 8.2, 6.4 Hz, 2H), 1.82 – 1.68 (m, 
2H), 1.50 – 1.37 (m, 3H), 1.39 – 1.22 (m, 11H), 0.91 – 0.84 (m, 3H). 13C NMR (101 MHz, 
CD3OD) δ 203.63, 163.49, 163.31, 146.99, 145.16, 133.21, 132.13, 131.77, 129.10, 128.89, 
128.71, 125.41, 116.44, 116.39, 69.61, 31.12, 30.95, 30.85, 30.73, 27.57, 27.04, 24.17, 23.40, 
14.88. 
 3.4.6 4-((E)-3-(4-decyloxy)phenyl)acryloyl)phenylboronic acid (6c). 4-
acetylphenylboronic acid (0.629 g, 3.81 mmol) and 4-(decyloxy)benzaldehyde (1.019 g, 3.81 
mmol) were reacted according to the general procedure. Yellow solids were collected with a 
yield of 84% (1.303 g). m.p. 109-163 °C. 
 3.4.7 4-((E)-3-(4-undecyloxy)phenyl)acryloyl)phenylboronic acid (7c). 4-
acetylphenylboronic acid (0.599 g, 3.62 mmol) and 4-(undecyloxy)benzaldehyde (1.018 g, 3.62 
mmol) were reacted according to the general procedure. Yellow solid were collected with a yield 
of 82% (1.247 g). m.p. 65-143 °C; 1H NMR (400 MHz, Methanol-d4) δ 8.00 (s, 1H), 7.84 (d, J = 
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8.8 Hz, 1H), 7.76 (d, J = 15.5 Hz, 1H), 7.68 (d, J = 8.7 Hz, 1H), 7.61 (d, J = 8.5 Hz, 1H), 7.59 – 
7.52 (m, 2H), 7.00 – 6.88 (m, 3H), 6.70 (d, J = 16.1 Hz, 1H), 4.06 (s, 0H), 4.02 – 3.92 (m, 3H), 
2.55 (d, J = 7.0 Hz, 2H), 2.27 – 2.01 (m, 2H), 1.85 – 1.65 (m, 4H), 1.53 – 1.18 (m, 24H), 0.96 (d, 
J = 6.7 Hz, 4H), 0.92 – 0.82 (m, 4H). 
 3.4.8 4-((E)-3-(4-dodecyloxy)phenyl)acryloyl)phenylboronic acid (8c). 4-
acetylphenylboronic acid (0.564 g, 3.44 mmol) and 4-(dodecyloxy)benzaldehyde (1.012 g, 3.44 
mmol) were reacted according to the general procedure. Pale yellow solids were gathered with a 
yield of 75% (1.121 g). 
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CHAPTER 4 
Results and Discussion 
4.1 Results and Discussion of Ether Synthesis 
4.1.1 Yields of 4-alkoxybenzaldehydes. Synthetic yields including cLogP values 
calculated from the 4-alkoxybenzaldehydes.  
Table 1 
Yields for 4-alkoxybenzaldehydes 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 4.1.2 Discussion of solubility. The partition coefficient (Log P) is a measurement of a 
compound’s solubility in a hydrophobic and hydrophilic solvent, usually octanol ant water. This 
S.No. Product cLogP Yield (%) 
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7.60 67 
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value establishes a compound’s hydrophilicity and gives an insight to how a drug will be 
metabolized in the body. High Log P values indicate that a compound is hydrophobic “water 
fearing” and is more likely to absorb/permeate through the lipid bilayers. A low score for the 
Log P value indicates that the drug is hydrophilic “water loving” and is more favored being that 
the drug will metabolize through the blood serum. Within the pharmaceutical industry an 
acceptable cLog P values is anything below a 5.0.    
 In regards to the solubility of the benzaldehydes, the solubility is completely dependent 
on the ether chain attached to the ring. Before the ether chain was added onto 4-
hydroxybenzaldehye, its cLogP value was 1.44, making it a hydrophilic compound. As the chain 
increased with carbons the value of cLogP increased. For that reason we can assume the 
additional carbons make the compounds more hydrophobic.   
 
Figure 4. 1H NMR of 4-(nonyloxy)benzaldehyde 
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4.1.3 Discussion of 1H NMR. The hydrocarbons on the ether chain, protons E-H, would 
have a chemical shift found between 0-3 ppm. Proton E is a doublet at 3.41 ppm, protons F 
shows a doublet of triplets at 1.83, proton G is a multiplet at 1.33 and proton H is a multiplet at 
0.88 ppm. The hydrogen closest to the oxygen atom, proton D, had a chemical shift more 
downfield at 4.03 ppm resulting in a triplet because of the deshielding from its neighboring 
oxygen atom.  Moving down the spectra towards the aromatic ring, the hydrogen on the benzene 
ring protons B shows a doublet at 7.82 ppm and proton C is a multiplet at 6.99 ppm. The 
aldehydic hydrogen, proton A, had the highest frequency at 9.87 ppm as a doublet because of the 
strong dipole moment from the carbonyl.  
4.2 Results and Discussion of 4-alkoxymethoxychalcone Synthesis 
 
4.2.1 Yields of 4-alkoxymethoxychalcones. Synthetic yields including cLogP values 
calculated from the 4-alkoxymethoxychalcones. Refer to Figure 2 for numbering sequence.  
Table 2 
Yields for 4-alkxoymethoxychalcones 
S.No. 
B-ring  A-ring 
Product Yield (%) cLogP 4’- 4- 
1b OCH3 
 
C5H11 
O
H3C
O
O
 
68 5.13 
2b OCH3 
 
C6H13 
O
H3C
O
O
 
81 5.59 
3b OCH3 
 
C7H15 
O
H3C
O
O
 
70 6.05 
4b OCH3 
 
C8H17 
O
H3C
O
O
 
58 6.52 
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5b OCH3 
 
C9H19 
O
OO
H3C
 
68 6.98 
6b OCH3 
 
C10H21 
O
H3C
O
O
 
91 7.45 
7b OCH3 
 
C11H23 
O
H3C
O
O
 
76 7.91 
8b OCH3 
 
C12H25 
O
H3C
O
O
 
70 8.37 
 
4.2.2 Discussion of solubility. In regards to the solubility of the methoxychalcones, it is 
assumed that the longer the ether chain the more nonpolar the compound is than the compounds 
with the shorter chains. Confirming this statement is the cLogP value from Table 2. The 
solubility value, when compared to its respected benzaldehyde starting material shows an 
increase in cLlogP value. This indicates that these compounds are more likely to metabolize 
through the lipid bilayers and would not be considered a target drug due to its high Log P values.  
4.2.3 Discussion of 1H and 13C NMR. To confirm that the methoxychalcones were 
synthesized we ran both a 1H NMR as well as a 13C NMR to compare them to their 
corresponding benzaldehyde starting material (compounds 1a-8a). Figure 5 is the full spectrum 
of the proton NMR for the nonane methoxychalcone. Figure 6 the highlights the aliphatic region 
of the compound while Figure 7 highlights the aromatic region. This compound was ran in 
deuterated chloroform (CDCl3) and the solvent peaks appear at 7.25 ppm. Within the aliphatic 
proton G, the methoxy proton is a triplet with a chemical shift at 4.0 ppm. Proton H is the 
methoxy proton attached to ring A is a singlet with a chemical shift at 3.9 ppm. Both the 
methoxy protons are slightly downfield than that of the methyl protons because of the 
deshielding affect oxygen has on the nucleus. In the ether chain are multiplets consisting of 
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protons I, K, J and L. Proton I is a CH2 group at 1.80 ppm, proton K are CH2 groups that are not 
equivalent but will show the same chemical shifts at 1.29 ppm. Proton J is another CH2 group at 
1.45 and proton L is the last peak at 0.9.  
 
Figure 5. 1H NMR of (E)-1-(4-methoxyphenyl)-3-(4-(nonyloxy)phenyl)prop-2-en-1-one. 
 
Figure 6. 1H NMR aliphatic region of (E)-1-(4-methoxyphenyl)-3-(4-(nonlyoxy)phenyl)prop-2-
en-1-one. 
In the aromatic region there are a series of doublets. Both benzene rings have two sets of 
doublets that are difficult to label each protons chemical shift, but the vinyilic protons have 
O
OH3C O
H
C
C
A
A
B
D
E
F
F
E
G
I
K
K
K
K J
LK
34 
 
doublets at 7.78 ppm (proton B) and 7.43 ppm (proton D). Normally vinyilic protons appear 
between 4.6-5.7 ppm. To differentiate between the peaks that coupled in the aromatic region, a 
two-dimensional nuclear resonance spectroscopy (2D NMR) was perform, specifically a 
correlation spectroscopy (COSY) (Figure 8). Protons A and C are located on benzene ring A, 
proton C is a doublet at 7.59 ppm and proton A is another doublet at 8.03 ppm. On the benzene 
ring B are protons E and F, proton E is a doublet at 6.98 ppm and F is another doublet at 6.92 
ppm. 
 
Figure 7. 1H NMR aromatic region of (E)-1-(4-methoxyphenyl)-3-(4-(nonlyoxy)phenyl)prop-2-
en-1-one. 
 The 13C NMR allowed us to see how the chemical backbone was arranged, and what 
functional groups are represented. The different peaks represent the varying environments of the 
carbons. Figure 9 is the representative 13C NMR of the nonane methoxychalcone. It has total of 
twenty five carbons in the chemical formula. 
Figure 8. 2D NMR COSY of (E)
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Figure 9. 13C NMR of (E)-1-(4-methoxyphenyl)-3-(4-(nonyloxy)phenyl)prop-2-en-1-one. 
 
4.3 Results and Discussions of 4-alkoxyboronic acid chalcone Synthesis 
4.3.1 Yields of 4-alkoxyboronic acid chalcones. Synthetic yields including cLogP 
values calculated from the 4-alkoxyboronic acid chalcones. Refer to Figure 2 for numbering 
sequence 
Table 3 
Yields for 4-alkoxyboronic acid chalcones 
S.No. 
B-ring  A-ring 
Product Yield (%) cLogP 4’- 4- 
1c B(OH)2 
 
C5H11 
B
HO
O
O
OH
 
 
3.30 
2c B(OH)2 
 
C6H13 
B
HO
O
O
OH
 
64 3.77 
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3c B(OH)2 
 
C7H15 
B
HO
O
O
OH
 
88 4.23 
4c B(OH)2 
 
C8H17 
B
HO
O
O
OH
 
58 4.69 
5c B(OH)2 
 
C9H19 
O
OB
HO
OH
 
67 5.16 
6c B(OH)2 
 
C10H21 
B
HO
O
O
OH
 
84 5.52 
7c B(OH)2 
 
C11H23 
B
HO
O
O
OH
 
82 6.09 
8c B(OH)2 
 
C12H25 
B
HO
O
O
OH
 
75 6.55 
  
 4.3.2 Discussion of solubility. The solubility of the boronic acid chalcones follows the 
trend with that of the others, as the chain increases in carbons the solubility increases. However 
because of the boronic acid group on the other side of the compound the cLogP value 
significantly dropped when compared to the methoxychalcones. This validates that by adding the 
boronic acid functional group, the compounds become more soluble allowing it to have more 
bioavailability. These compounds would be promising in the pharmaceutical industry due to its 
low cLogP values indicating that they would metabolize through the blood serum. 
4.3.3 Discussion of 1H and 13C NMR. The boronic acid chalcones were all ran in 
deuterated methanol which has two peaks with chemical shifts of 4.8 ppm and 3.3 ppm. Similar 
to the methoxy chalcones’ proton NMRs, Figure 10 showcases the full proton NMR, Figure 11 is 
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the aliphatic region, and Figure 12 is the aromatic region. The chemical shifts are somewhat 
similar to that of the methoxy chalcone in the aliphatic region with the exception of only 
expecting one methoxy proton with a chemical shift around 4.0 ppm being that the boronic acid 
chalcones have hydroxyl protons attached to its second ring instead of an extra methoxy group. 
The same follows true for the aromatic region, both the vinylic protons and aromatic protons 
have similar chemical shifts with exception of now having an extra peak that appears at 8.01 
ppm representing the hydroxyl protons on the boron. Literature confirms that when boronic acid 
is attached to a benzene ring, there is an expected chemical shift of 7.25-8.29 ppm (Bruns, 
Sinnwell, & Voss, 2003).   
 
Figure 10. 1H NMR of 4-((E)-3-(4-(nonyloxy)phenyl)acryloyl)phenylboronic acid.  
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Figure 11. 1H NMR aliphatic region of 4-((E)-3-(4-(nonyloxy)phenyl)acryloyl)phenylboronic 
acid. 
Figure 12. 1H NMR aromatic region of 4-((E)-3-(4-(nonyloxy)phenyl)acryloyl)phenylboronic 
acid. 
40 
 
 Figure 13 is the representative 13C NMR of the nonane boronic acid chalcone.Peaks are 
not as pronounced due to the solubility of the compound in the solvent. Again similar to that of 
the methoxy chalcone we expect to see twenty five peaks for each of the carbons in the 
compound, but eighteen different environments. The only difference is the slight down field shift 
of the peaks that might be due to the boron. The biggest difference between the 13C NMR of the 
methoxy and boronic acid chalcones is the carbonyl peak.  In the methoxy spectrum the carbonyl 
peak appears at 188.59 ppm but now in the boronic acid spectrum has a down field shift at 
203.63 ppm. The presence of only one methoxy carbon instead of two signifies that there is 
another difference between both the methoxy and boronic acid spectrums.   
 
Figure 13. 13C NMR of ((E)-3-(4-(nonyloxy)phenyl)arcyloyl)phenylboronic acid 
 By comparing the NMR data from both the 1H NMR and 13C NMR of each chalcone 
confirms t that there is a difference between the methoxychalcones and the boronic acid 
chalcones. This difference can be made by the aliphatic regions of the 1H NMR and by different 
carbonyl shifts in the 13C NMR.  
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CHAPTER 5 
Conclusion and Future Research 
We have reported an attempt to synthesize twenty four chalcone derivatives. To the best 
of our knowledge, thirteen of our chalcone derivatives have never being reported, this 
investigation namely, five methoxy chalcones (4b-8b) and eight boronic acid chalcones (1c-8c). 
The benzaldehyde compounds had much success with the Williamson Ether synthesis. An extra 
step was added to ensure that the compounds were pure; the distillation via Kugelrohr. The 
benzaldehydes that were synthesized are commercially available, but do not have any reported 
melting point from their respected companies. 
Out of the three reactions, the boronic acid chalcones took the most effort to recover. The 
degree of difficulty came about when it came time to recrystallize the compounds. This was 
partially due to the solubility of the compound and because of that three of the compounds were 
not recovered. Another issue we encountered when synthesizing both sets of chalcones was 
having starting material in the products. Evidence of the starting material, mainly benzaldehye, 
showed up in the NMR spectra and could be the reason to why recrystallizing the compound had 
a degree of difficulty. To deal with this issue an excess of acetophenone could be used instead of 
equal molar quantity.  
Once we recovered the three boronic acid chalcones lost in recrystallization, (1c, 4c and 
8c) we want to add on with the discovery and add the butane and propane boronic acid chalcones 
to the library, neither of which have been reported. The next step for both sets of chalcones is to 
send them to the National Institute of Health Developmental Therapeutics Program to be 
screened on cancer cell lines. This step will help with the development of a structure-activity 
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relationship and to see if boronic acid will indeed have more biological availability than that of a 
methoxy group as well as see if the ether chain has any affect on cancer.  
 During this research, we also encountered a crystal form of a chalcone that we 
attempted to synthesize in the past (Figure 14). This too gives great insight to the characteristics 
of chalcones. In the future we have hopes to further study this crystal and attempt to form 
crystals with the other chalcones.  
 
O
O
(E)-3-(4-(heptyloxy)phenyl)-1-phenylprop-2-en-1-one
 
 
 
 
Figure 14. Chalcone crystal structures. 
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Appendix A 
1H NMR 
4-(pentyloxy)benzaldehyde (1a) 
 
4-(hexyloxy)benzaldehyde (2a) 
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4-(heptyloxy)benzaldehyde (3a) 
 
4-(octyloxy)benzaldehyde (4a) 
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4-(nonyloxy)benzaldehyde (5a) 
 
4-(decyloxy)benzaldehyde (6a) 
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4-(undecyloxy)benzaldehyde (7a) 
 
4-(dodecyloxy)benzaldehyde (8a) 
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(E)-1-(4-methoxyphenyl)-3-(4-(pentyloxy)phenyl)prop-2-en-1-one (1b) 
 
(E)-1-(4-(hexyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (2b) 
 
53 
 
(E)- 3-(4-(heptyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (3b) 
 
(E)-1-(4-methoxyphenyl)-3-(4-(octyloxy)phenyl)prop-2-en-1-one (4b) 
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(E)- 3-(4-(decyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (6b) 
 
(E)-1-(4-methoxyphenyl)-3-(4-(undecyloxy)phenyl)prop-2-en-1-one (7b) 
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(E)-3-(4-(dodecyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (8b) 
 
4-((E)-3-(4-(hexyloxy)phenyl)acryloyl)phenylboronic acid (2c) 
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4-((E)-3-(4-heptyloxy)phenyl)acryloyl)phenyloboronic acid (3c) 
 
4-((E)-3-(4-undecyloxy)phenyl)acryloyl)phenylboronic acid (7c) 
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Appendix B 
13C NMR 
(E)-1-(4-(hexyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (2b )
 
(E)- 3-(4-(heptyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (3b)
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(E)-1-(4-methoxyphenyl)-3-(4-(octyloxy)phenyl)prop-2-en-1-one (4b)
 
(E)-1-(4-methoxyphenyl)-3-(4-(nonyloxy)phenyl)prop-2-en-1-one (5b) 
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(E)- 3-(4-(decyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (6b) 
 
(E)-1-(4-methoxyphenyl)-3-(4-(undecyloxy)phenyl)prop-2-en-1-one (7b) 
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(E)-3-(4-(dodecyloxy)phenyl)-1-(4-methoxyphenyl)prop-2-en-1-one (8b) 
 
4-((E)-3-(4-(hexyloxy)phenyl)acryloyl)phenylboronic acid (2c) 
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4-((E)-3-(4-heptyloxy)phenyl)acryloyl)phenyloboronic acid (3c) 
 
4-((E)-3-(4-undecyloxy)phenyl)acryloyl)phenylboronic acid (7c) 
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Appendix C 
Chalcone Crystal Tables 
Table 1: Data collection details for Franks2. 
Axis dx/
mm 
2θ/° ω/° φ/° χ/° Width/
° 
Frame Time/s λ/Å 
Voltage/
kV 
Current/
mA 
Tem/
K 
Omega 44.765 
-
20.0
0 
340.0
0 0.00 
35.0
2 0.50 360 10.00 
0.70
973 50 1.0 
200.0
0 
Omega 44.765 
-
20.0
0 
340.0
0 
120.0
0 
35.0
2 0.50 360 10.00 
0.70
973 50 1.0 
200.0
0 
Omega 44.765 
-
20.0
0 
340.0
0 
240.0
0 
35.0
2 0.50 360 10.00 
0.70
973 50 1.0 
200.0
0 
A total of 1080 frames were collected. The total exposure time was 3.00 hours. The integration 
of the data using a triclinic unit cell yielded a total of 8223 reflections to a maximum θ angle of 
25.05° (0.84 Å resolution), of which 3228 were independent (average redundancy 2.547, 
completeness = 98.0%, Rint = 5.44%, Rsig = 8.92%) and 2386 (73.92%) were greater than 
2σ(F2).The final cell constants of a = 5.6069(9) Å, b = 7.7822(13) Å, c = 22.864(4) Å, α = 
81.101(5)°, β = 85.571(5)°, γ = 69.879(4)°, volume = 925.2(3) Å3, are based upon the refinement 
of the XYZ-centroids of 2559 reflections above 20 σ(I) with 5.404° < 2θ < 49.74°.Data were 
corrected for absorption effects using the multi-scan method (SADABS). The ratio of minimum 
to maximum apparent transmission was 0.627. The calculated minimum and maximum 
transmission coefficients (based on crystal size) are 0.9648 and 0.9885. 
 
The structure was solved and refined using the Bruker SHELXTL Software Package, using the 
space group P -1, with Z = 2 for the formula unit, C22H26O2.The final anisotropic full-matrix 
least-squares refinement on F2 with 228 variables converged at R1 = 6.51%, for the observed 
data and wR2 = 20.77% for all data. The goodness-of-fit was 1.190. The largest peak in the final 
difference electron density synthesis was 0.552 e-/Å3 and the largest hole was -0.276 e-/Å3 with 
an RMS deviation of 0.116 e-/Å3. On the basis of the final model, the calculated density was 
1.157 g/cm3 and F(000), 348 e-. 
Table 2. Sample and crystal data for Franks2.  
Identification code Franks2 
Chemical formula C22H26O2 
Formula weight 322.43 
Temperature 200(2) K 
Wavelength 0.71073 Å 
Crystal size 0.16 x 0.26 x 0.50 mm 
Crystal habit colorless plate 
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Crystal system triclinic 
Space group P -1 
Unit cell dimensions a = 5.6069(9) Å α = 81.101(5)° 
 
b = 7.7822(13) Å β = 85.571(5)° 
 
c = 22.864(4) Å γ = 69.879(4)° 
Volume 925.2(3) Å3 
 
Z 2 
Density (calculated) 1.157 Mg/cm3 
Absorption coefficient 0.072 mm-1 
F(000) 348 
 
Table 3. Data collection and structure refinement for Franks2.  
Diffractometer Bruker Smart X2S Diffractometer 
Radiation source microfocus sealed tube, Mo Kα 
Theta range for data 
collection 0.90 to 25.05° 
Index ranges -6<=h<=6, -9<=k<=9, -27<=l<=27 
Reflections collected 8223 
Independent reflections 3228 [R(int) = 0.0544] 
Coverage of independent 
reflections 98.0% 
Absorption correction multi-scan 
Max. and min. 
transmission 0.9885 and 0.9648 
Structure solution 
technique direct methods 
Structure solution program SHELXS-97 (Sheldrick, 2008) 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-97 (Sheldrick, 2008) 
Function minimized Σ w(Fo2 - Fc2)2 
Data / restraints / 
parameters 3228 / 0 / 228 
Goodness-of-fit on F2 1.190 
Final R indices 2386 data; I>2σ(I) 
R1 = 0.0651, wR2 = 
0.1697 
 
all data R1 = 0.0854, wR2 = 0.2077 
Weighting scheme w=1/[σ
2(Fo2)+(0.0979P)2+0.0000P] 
where P=(Fo2+2Fc2)/3 
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Extinction coefficient 0.0570(120) 
Largest diff. peak and hole 0.552 and -0.276 eÅ-3 
R.M.S. deviation from 
mean 
0.116 eÅ-3 
 
Table 4. Atomic coordinates and equivalent 
isotropic atomic displacement parameters 
(Å2) for Franks2.  
U(eq) is defined as one third of the trace of the 
orthogonalized Uij tensor.  
 
x/a y/b z/c U(eq) 
C11 0.6979(3) 0.2351(2) 0.61650(8) 0.0373(5) 
C12 0.8440(4) 0.2089(2) 0.66932(9) 0.0401(5) 
C10 0.8257(3) 0.1746(2) 0.56517(8) 0.0421(5) 
O1 0.2981(2) 0.31056(16) 0.46311(5) 0.0443(4) 
O2 0.1747(3) 0.1737(2) 0.75749(6) 0.0669(5) 
C1 0.2058(5) 0.2485(3) 0.08678(10) 0.0809(11) 
C2 0.0852(4) 0.2923(3) 0.14694(9) 0.0610(6) 
C3 0.2731(4) 0.2277(2) 0.19622(8) 0.0480(5) 
C4 0.1557(4) 0.2757(2) 0.25614(8) 0.0462(5) 
C5 0.3482(3) 0.2293(2) 0.30457(8) 0.0437(5) 
C6 0.2296(3) 0.2862(2) 0.36364(8) 0.0424(5) 
C7 0.4238(4) 0.2392(2) 0.41054(8) 0.0412(5) 
C8 0.4414(3) 0.2829(2) 0.51157(8) 0.0360(5) 
C9 0.7019(4) 0.1964(2) 0.51296(8) 0.0425(5) 
C13 0.7633(4) 0.2386(2) 0.72417(9) 0.0406(5) 
C14 0.9482(4) 0.2096(2) 0.77038(9) 0.0440(5) 
C15 0.8612(4) 0.2268(2) 0.83310(8) 0.0417(5) 
C16 0.6110(4) 0.3095(3) 0.85062(9) 0.0494(6) 
C17 0.5449(4) 0.3288(3) 0.90944(9) 0.0585(6) 
C18 0.7295(5) 0.2628(3) 0.95184(10) 0.0613(6) 
C19 0.3094(3) 0.3496(2) 0.56215(8) 0.0401(5) 
C20 0.4342(3) 0.3248(2) 0.61376(8) 0.0390(5) 
C21 0.9803(4) 0.1774(3) 0.93508(9) 0.0593(6) 
C22 0.0452(4) 0.1600(3) 0.87671(9) 0.0502(6) 
 
Table 5. Bond lengths (Å) for Franks2.  
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C11-C10 1.386(3) C11-C20 1.403(3) 
C11-C12 1.460(2) C12-C13 1.327(3) 
C12-H13 0.934(19) C10-C9 1.386(2) 
C10-H10 0.949 O1-C8 1.365(2) 
O1-C7 1.434(2) O2-C14 1.226(2) 
C1-C2 1.519(3) C1-H1A 0.98 
C1-H1B 0.98 C1-H1C 0.98 
C2-C3 1.508(2) C2-H2A 0.99 
C2-H2B 0.99 C3-C4 1.516(3) 
C3-H3A 0.99 C3-H3B 0.99 
C4-C5 1.521(2) C4-H4A 0.99 
C4-H4B 0.99 C5-C6 1.518(2) 
C5-H5A 0.99 C5-H5B 0.99 
C6-C7 1.502(2) C6-H6A 0.99 
C6-H6B 0.99 C7-H7A 0.99 
C7-H7B 0.99 C8-C9 1.383(3) 
C8-C19 1.394(2) C9-H9 0.95 
C13-C14 1.475(2) C13-H12 0.95(2) 
C14-C15 1.490(3) C15-C16 1.384(3) 
C15-C22 1.399(2) C16-C17 1.384(3) 
C16-H16 0.95 C17-C18 1.382(3) 
C17-H17 0.95 C18-C21 1.385(3) 
C18-H18 0.95 C19-C20 1.372(2) 
C19-H19 0.95 C20-H20 0.95 
C21-C22 1.371(3) C21-H21 0.95 
C22-H22 0.95 
  
 
Table 6. Bond angles (°) for Franks2.  
C10-C11-C20 117.38(16) C10-C11-C12 118.82(17) 
C20-C11-C12 123.75(17) C13-C12-C11 129.55(19) 
C13-C12-H13 117.3(11) C11-C12-H13 113.1(11) 
C9-C10-C11 122.48(17) C9-C10-H10 118.8 
C11-C10-H10 118.7 C8-O1-C7 118.07(14) 
C2-C1-H1A 109.5 C2-C1-H1B 109.5 
H1A-C1-H1B 109.5 C2-C1-H1C 109.5 
H1A-C1-H1C 109.5 H1B-C1-H1C 109.5 
C3-C2-C1 113.5(2) C3-C2-H2A 108.9 
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C1-C2-H2A 108.9 C3-C2-H2B 108.9 
C1-C2-H2B 108.9 H2A-C2-H2B 107.7 
C2-C3-C4 113.85(18) C2-C3-H3A 108.8 
C4-C3-H3A 108.8 C2-C3-H3B 108.8 
C4-C3-H3B 108.8 H3A-C3-H3B 107.7 
C3-C4-C5 114.00(17) C3-C4-H4A 108.8 
C5-C4-H4A 108.8 C3-C4-H4B 108.8 
C5-C4-H4B 108.8 H4A-C4-H4B 107.6 
C6-C5-C4 113.52(16) C6-C5-H5A 108.9 
C4-C5-H5A 108.9 C6-C5-H5B 108.9 
C4-C5-H5B 108.9 H5A-C5-H5B 107.7 
C7-C6-C5 112.37(15) C7-C6-H6A 109.1 
C5-C6-H6A 109.1 C7-C6-H6B 109.1 
C5-C6-H6B 109.1 H6A-C6-H6B 107.9 
O1-C7-C6 108.46(14) O1-C7-H7A 110.0 
C6-C7-H7A 110.0 O1-C7-H7B 110.0 
C6-C7-H7B 110.0 H7A-C7-H7B 108.4 
O1-C8-C9 124.51(17) O1-C8-C19 115.95(15) 
C9-C8-C19 119.54(16) C8-C9-C10 119.06(18) 
C8-C9-H9 120.5 C10-C9-H9 120.5 
C12-C13-C14 119.98(18) C12-C13-H12 121.8(11) 
C14-C13-H12 118.2(11) O2-C14-C13 120.41(18) 
O2-C14-C15 119.19(16) C13-C14-C15 120.39(17) 
C16-C15-C22 118.12(18) C16-C15-C14 124.01(17) 
C22-C15-C14 117.85(18) C15-C16-C17 120.99(18) 
C15-C16-H16 119.5 C17-C16-H16 119.5 
C18-C17-C16 120.0(2) C18-C17-H17 120.0 
C16-C17-H17 120.0 C17-C18-C21 119.6(2) 
C17-C18-H18 120.2 C21-C18-H18 120.2 
C20-C19-C8 120.69(17) C20-C19-H19 119.7 
C8-C19-H19 119.7 C19-C20-C11 120.81(17) 
C19-C20-H20 119.6 C11-C20-H20 119.6 
C22-C21-C18 120.18(19) C22-C21-H21 119.9 
C18-C21-H21 119.9 C21-C22-C15 121.1(2) 
C21-C22-H22 119.5 C15-C22-H22 119.5 
 
Table 7. Anisotropic atomic displacement parameters (Å2) for 
Franks2.  
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The anisotropic atomic displacement factor exponent takes the form: -2π2[ h2 a*2 
U11 + ... + 2 h k a* b* U12 ]  
 
U11 U22 U33 U23 U13 U12 
C11 0.0381(11) 0.0313(8) 0.0435(11) -0.0044(7) -0.0017(9) -0.0132(8) 
C12 0.0350(12) 0.0382(9) 0.0466(12) -0.0038(8) -0.0019(9) -0.0124(8) 
C10 0.0333(11) 0.0415(9) 0.0507(12) -0.0119(8) -0.0004(9) -0.0094(8) 
O1 0.0407(8) 0.0490(7) 0.0374(8) -0.0082(6) -0.0044(6) -0.0059(6) 
O2 0.0403(10) 0.1027(12) 0.0556(10) -0.0106(8) -0.0044(7) -0.0207(8) 
C1 0.120(3) 0.0757(16) 0.0502(15) -0.0115(11) 
-
0.0160(14) 
-
0.0329(16) 
C2 0.0783(17) 0.0532(11) 0.0493(13) -0.0081(10) 
-
0.0188(12) 
-
0.0151(11) 
C3 0.0554(13) 0.0416(10) 0.0454(12) -0.0049(8) -0.0060(10) -0.0138(9) 
C4 0.0508(13) 0.0389(9) 0.0455(12) -0.0044(8) -0.0085(10) -0.0098(9) 
C5 0.0453(12) 0.0409(9) 0.0430(12) -0.0065(8) -0.0041(9) -0.0113(9) 
C6 0.0471(13) 0.0382(9) 0.0398(11) -0.0050(8) -0.0019(9) -0.0115(9) 
C7 0.0439(12) 0.0382(9) 0.0398(11) -0.0096(8) 0.0034(9) -0.0107(8) 
C8 0.0401(11) 0.0301(8) 0.0372(10) -0.0039(7) -0.0022(8) -0.0111(8) 
C9 0.0402(12) 0.0430(9) 0.0439(11) -0.0131(8) 0.0021(9) -0.0113(8) 
C13 0.0365(13) 0.0422(10) 0.0437(12) -0.0013(8) -0.0057(9) -0.0149(9) 
C14 0.0384(12) 0.0448(10) 0.0488(12) -0.0009(8) -0.0066(9) -0.0151(9) 
C15 0.0467(13) 0.0402(9) 0.0432(11) -0.0018(8) -0.0080(9) -0.0212(9) 
C16 0.0419(13) 0.0563(11) 0.0505(13) -0.0072(9) -0.0068(10) -0.0160(9) 
C17 0.0539(14) 0.0694(13) 0.0537(13) -0.0145(10) 0.0014(10) 
-
0.0207(11) 
C18 0.0736(17) 0.0729(14) 0.0446(12) -0.0104(10) 
-
0.0018(11) 
-
0.0328(13) 
C19 0.0346(11) 0.0402(9) 0.0420(11) -0.0050(8) -0.0004(8) -0.0085(8) 
C20 0.0378(11) 0.0401(9) 0.0369(10) -0.0046(7) 0.0025(8) -0.0115(8) 
C21 0.0655(16) 0.0686(13) 0.0475(13) 0.0002(10) -0.0155(11) 
-
0.0279(12) 
C22 0.0470(13) 0.0539(11) 0.0502(13) -0.0005(9) -0.0103(10) 
-
0.0185(10) 
 
 
